AQR Capital Management’s Keros Therapeutics KROS Stock Holding History

AQR Capital Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Buy	967,859 +561,296	+138%	+$6.25M	﹤0.01%	1557
2026 Q1	$4.49M	Buy	406,563 +226,020	+125%	+$3.49M	﹤0.01%	1820
2025 Q4	$3.68M	Sell	180,543 -23,808	-12%	-$418K	﹤0.01%	1764
2025 Q3	$3.23M	Buy	204,351 +133,701	+189%	+$1.98M	﹤0.01%	1698
2025 Q2	$943K	Buy	70,650 +48,514	+219%	+$655K	﹤0.01%	2239
2025 Q1	$226K	Buy	+22,136	New	+$257K	﹤0.01%	2824
2023 Q3	–	Sell	-11,441	Closed	-$460K	–	2344
2023 Q2	$460K	Buy	11,441 +3,850	+51%	+$169K	﹤0.01%	1813
2023 Q1	$324K	Buy	+7,591	New	+$383K	﹤0.01%	1924

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

AQR Capital Management's KROS Position: Q2 2026 in Review

AQR Capital Management increased its Keros Therapeutics (KROS) stake by 138% in Q2 2026, buying an estimated $6.25M and bringing the position to 967,859 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

AQR Capital Management first reported a position in KROS in Q1 2023 and has held it in 8 quarters since. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

AQR Capital Management held 967,859 shares of Keros Therapeutics worth $10.4M as of Q2 2026.
AQR Capital Management bought 561,296 Keros Therapeutics shares in Q2 2026, an estimated $6.25M.
Keros Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1557 holding.
AQR Capital Management first reported a position in Keros Therapeutics in Q1 2023 and has held it in 8 quarters since.
133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.